Bukwang Pharmaceutical said that it would promote and market Aprovel and CoAprovel, Angiotensin II receptor blocker (ARB) class hypertension treatment, jointly with Sanofi Aventis Korea. The two companies signed the agreement on Dec. 13.
|Bukwang Pharmaceutical headquarters in Daebang-dong, Seoul.|
Under the accord, Sanofi-Aventis Korea and Bukwang will co-manage marketing and sales of Aprovel and CoAprovel to local hospitals and clinics.
According to UBIST, a market research firm, the prescription performance of the two treatments was 20 billion won ($17.1 million) in 2018.
Aprovel is an antihypertensive agent based on the Irbesartan component of the ARB family. The drug has a clinical basis for treating diabetic kidney disease in patients with diabetes as well as hypertension, making it an effective antihypertensive agent for hypertensive patients with diabetes.
CoAprovel, which combines Aprovel with a diuretic, can be expected to have a blood pressure-lowering effect even in patients who require combination therapy.
“The joint sales of the Aprovel family will lay the groundwork for the circulatory sector, promote mutual growth through collaboration with Sanofi-Aventis Korea, and will serve as a driving force for the company in achieving 200 billion won in 2020 sales,” a Bukwang official said.